

Mark A Perazella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5743040/publications.pdf>

Version: 2024-02-01

158
papers

7,447
citations

44069

48
h-index

58581

82
g-index

163
all docs

163
docs citations

163
times ranked

8474
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2214-2222.	0.7	11
2	Severe AKI in a Patient on Multiple Antimicrobial Agents for Leg Infection. <i>Kidney360</i> , 2022, 3, 405-406.	2.1	1
3	Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. , 2022, 10, e004421.		19
4	Drug-Induced Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1220-1233.	4.5	75
5	Urine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy. <i>Practical Laboratory Medicine</i> , 2022, 30, e00271.	1.3	4
6	Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?. <i>Kidney360</i> , 2022, 3, 550-553.	2.1	3
7	Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. <i>Kidney International Reports</i> , 2022, 7, 1939-1950.	0.8	7
8	Urine interleukin-9 and tumor necrosis factor- $\hat{\pm}$ for prognosis of human acute interstitial nephritis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1851-1858.	0.7	26
9	Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. <i>Radiology</i> , 2021, 298, 28-35.	7.3	110
10	Onconephrology: The intersections between the kidney and cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 47-77.	329.8	78
11	PARP inhibitors and the Kidney. <i>Journal of Onco-Nephrology</i> , 2021, 5, 42-47.	0.6	4
12	In Case of a Pandemic, Pivot: Moving the National Kidney Foundation Spring Clinical Meeting Online. <i>American Journal of Kidney Diseases</i> , 2021, 77, 1-3.	1.9	3
13	Genes, COVID-19 and phenotype. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1485-1487.	2.9	0
14	Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1301-1306.	2.9	12
15	The Challenges of Acute Interstitial Nephritis: Time to Standardize. <i>Kidney360</i> , 2021, 2, 1051-1055.	2.1	5
16	The Crystalline Nephropathies. <i>Kidney International Reports</i> , 2021, 6, 2942-2957.	0.8	26
17	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	1.4	5
18	Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. <i>Kidney International</i> , 2020, 97, 62-74.	5.2	121

#	ARTICLE	IF	CITATIONS
19	Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 289-297.	4.5	50
20	Improving Cancer Care for Patients With Chronic Kidney Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 188-192.	1.6	11
21	In Reply to "Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus". <i>Kidney Medicine</i> , 2020, 2, 501.	2.0	0
22	Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY. <i>Kidney360</i> , 2020, 1, 1192-1194.	2.1	0
23	Assessment of Interobserver Reliability of Nephrologist Examination of Urine Sediment. <i>JAMA Network Open</i> , 2020, 3, e2013959.	5.9	17
24	NSAIDs in CKD: Are They Safe?. <i>American Journal of Kidney Diseases</i> , 2020, 76, 546-557.	1.9	99
25	How to determine kidney function in cancer patients?. <i>European Journal of Cancer</i> , 2020, 132, 141-149.	2.8	20
26	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.8	71
27	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020, 97, 1117-1129.	5.2	407
28	Adverse Drug Effects in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1075-1077.	4.5	9
29	The kidney's "cancer connection continues to grow. <i>Journal of Onco-Nephrology</i> , 2020, 4, 26-27.	0.6	1
30	Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. <i>Radiology</i> , 2020, 294, 660-668.	7.3	309
31	Acute kidney injury in a patient with lymphoma. <i>Journal of Onco-Nephrology</i> , 2020, 4, 66-67.	0.6	1
32	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary. <i>Kidney360</i> , 2020, 1, 166-168.	2.1	15
33	COVID-19 therapeutic options for patients with kidney disease. <i>Kidney International</i> , 2020, 97, 1297-1298.	5.2	37
34	A Patient with Nephrotic Syndrome and Acute Flank Pain. <i>Kidney360</i> , 2020, 1, 74-75.	2.1	0
35	Clinical Images in Nephrology and Dialysis. <i>Kidney360</i> , 2020, 1, 5-5.	2.1	0
36	Introduction to <i>Kidney360</i> . <i>Kidney360</i> , 2020, 1, 3-4.	2.1	0

#	ARTICLE	IF	CITATIONS
37	Atypical urinary crystals in a patient with acute kidney injury. <i>Journal of Onco-Nephrology</i> , 2019, 3, 169-170.	0.6	1
38	Diagnosing acute interstitial nephritis: considerations for clinicians. <i>CKJ: Clinical Kidney Journal</i> , 2019, , .	2.9	9
39	Crying kidneys: Bilateral renal contrast leak. <i>Journal of Onco-Nephrology</i> , 2019, 3, 171-173.	0.6	0
40	The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 185-197.	1.4	10
41	The changing of the guard. <i>Seminars in Dialysis</i> , 2019, 32, 482-484.	1.3	0
42	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.2	47
43	Acute Kidney Injury Related to Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1828.	7.4	3
44	AKI in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1077-1079.	4.5	34
45	The nephrotoxicity of new immunotherapies. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 513-521.	3.1	12
46	Evolution of the kidney's cancer connection. <i>Journal of Onco-Nephrology</i> , 2019, 3, 88-91.	0.6	0
47	Acute kidney injury in the patient with cancer. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 295-308.	2.2	41
48	Drug-induced acute kidney injury: diverse mechanisms of tubular injury. <i>Current Opinion in Critical Care</i> , 2019, 25, 550-557.	3.2	119
49	Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol. <i>Kidney International Reports</i> , 2019, 4, 30-39.	0.8	10
50	Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. <i>Kidney International Reports</i> , 2019, 4, 494-499.	0.8	13
51	Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019. <i>American Journal of Kidney Diseases</i> , 2019, 73, 258-272.	1.9	112
52	A Hospital-Based Program to Reduce Central Line-Associated Bloodstream Infections among Hospitalized Patients Receiving Hemodialysis Using a Central Venous Catheter for Vascular Access. <i>Nephrology Nursing Journal</i> , 2019, 46, 587-590.	0.2	1
53	Renal cell carcinoma for the nephrologist. <i>Kidney International</i> , 2018, 94, 471-483.	5.2	69
54	Introduction to Nephro pharmacology for the Clinician. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1083-1084.	4.5	2

#	ARTICLE	IF	CITATIONS
55	Pharmacology behind Common Drug Nephrotoxicities. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1897-1908.	4.5	148
56	A Rarely Recognized Cause of Acute Kidney Injury in Rhabdomyolysis. American Journal of the Medical Sciences, 2018, 356, e27.	1.1	1
57	Opening an onconeurology clinic: recommendations and basic requirements. Nephrology Dialysis Transplantation, 2018, 33, 1503-1510.	0.7	31
58	Cancer drugs and the glomerulus. Journal of Onco-Nephrology, 2018, 2, 78-91.	0.6	2
59	The adverse kidney effects of cancer immunotherapies. Journal of Onco-Nephrology, 2018, 2, 56-68.	0.6	2
60	The authors reply. Kidney International, 2018, 94, 1238-1239.	5.2	2
61	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. Journal of the American Society of Nephrology: JASN, 2018, 29, 2039-2052.	6.1	121
62	Cardiorenal complications of immune checkpoint inhibitors. Nature Reviews Nephrology, 2018, 14, 571-588.	9.6	80
63	Anticancer Drug-Induced Acute Kidney Injury. Kidney International Reports, 2017, 2, 504-514.	0.8	81
64	Clinical Approach to Diagnosing Acute and Chronic Tubulointerstitial Disease. Advances in Chronic Kidney Disease, 2017, 24, 57-63.	1.4	57
65	The Role of PET Scanning in the Evaluation of Patients With Kidney Disease. Advances in Chronic Kidney Disease, 2017, 24, 154-161.	1.4	8
66	Acute Kidney Injury in Patients with Cancer. New England Journal of Medicine, 2017, 376, 1770-1781.	27.0	177
67	Impact of Regular or Extended Hemodialysis and Hemodiafiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports, 2017, 2, 1050-1058.	0.8	15
68	Kidney Injury and Repair Biomarkers in Marathon Runners. American Journal of Kidney Diseases, 2017, 70, 252-261.	1.9	81
69	Drug-Induced Acute Interstitial Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2046-2049.	4.5	89
70	Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. American Journal of Physiology - Renal Physiology, 2017, 313, F951-F954.	2.7	17
71	Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrology Dialysis Transplantation, 2017, 32, 1089-1097.	0.7	38
72	AKI in Multiple Myeloma: Paraproteins, Metabolic Disturbances, and Drug Toxicity. Journal of Onco-Nephrology, 2017, 1, 188-197.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Crizotinib: Renal Safety Evaluation. Journal of Onco-Nephrology, 2017, 1, 49-56.	0.6	12
74	Growth of the Kidneyâ€“Cancer Connection. Journal of Onco-Nephrology, 2017, 1, 71-73.	0.6	1
75	New Horizons in Nephrology: Update in Onco-Nephrology. Journal of Onco-Nephrology, 2017, 1, 147-150.	0.6	2
76	Diagnostic Testing in AKI: Let's Move the Field Forward. Journal of Hospital Medicine, 2017, 12, 380-381.	1.4	0
77	Severe Orthostatic Hypotension Complicating Multiple Myeloma. Journal of Onco-Nephrology, 2017, 1, e8-e12.	0.6	0
78	Cancer and Mortality in Solid-Organ Transplantation: Preventable or Inevitable?. American Journal of Kidney Diseases, 2016, 68, 839-842.	1.9	9
79	Mistakes We Make in Dialysis: An Introduction. Seminars in Dialysis, 2016, 29, 257-257.	1.3	0
80	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. Journal of Clinical Oncology, 2016, 34, 2429-2430.	1.6	5
81	Paraproteinâ€“Related Kidney Disease: Attack of the Killer M Proteins. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2256-2259.	4.5	7
82	Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal of Kidney Diseases, 2016, 68, 287-291.	1.9	253
83	PPIs and kidney disease: from AIN to CKD. Journal of Nephrology, 2016, 29, 611-616.	2.0	77
84	American Society of Nephrology Quiz and Questionnaire 2015: ESRD/RRT. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1313-1320.	4.5	2
85	The renal effects of ALK inhibitors. Investigational New Drugs, 2016, 34, 643-649.	2.6	34
86	Checkmate: kidney injury associated with targeted cancer immunotherapy. Kidney International, 2016, 90, 474-476.	5.2	30
87	Phosphate enemas and GFR decline: itâ€™s premature to sound the alarm. Kidney International, 2016, 90, 13-15.	5.2	1
88	Calcium oxalate crystalluria points to primary hyperoxaluria type 1. Kidney International, 2016, 89, 250.	5.2	6
89	American Society of Nephrology Quiz and Questionnaire 2015: Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 884-890.	4.5	1
90	American Society of Nephrology Quiz and Questionnaire 2015. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 735-744.	4.5	0

#	ARTICLE	IF	CITATIONS
91	American Society of Nephrology Quiz and Questionnaire 2015: Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1114-1122.	4.5	0
92	Commentary. Clinical Chemistry, 2016, 62, 440-441.	3.2	0
93	The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. Journal of the American Society of Nephrology: JASN, 2016, 27, 2227-2237.	6.1	79
94	Nephrologists as Educators. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 176-189.	4.5	14
95	Onco-nephrology: a decalogue: Table 1. Nephrology Dialysis Transplantation, 2016, 31, 515-519.	0.7	63
96	A case of crystalline nephropathy. Kidney International, 2015, 87, 1265-1266.	5.2	7
97	Crystalline-induced kidney disease: a case for urine microscopy. CKJ: Clinical Kidney Journal, 2015, 8, 131-136.	2.9	23
98	Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. Nephrology Dialysis Transplantation, 2015, 30, 1979-1988.	0.7	31
99	Acute Kidney Injury and Mortality in the Elderly: Add Atypical Antipsychotics to the List. American Journal of Kidney Diseases, 2015, 65, 655-658.	1.9	2
100	American Society of Nephrology Quiz and Questionnaire 2014. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 530-539.	4.5	4
101	New drug toxicities in the onco-nephrology world. Kidney International, 2015, 87, 909-917.	5.2	70
102	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1287-1290.	4.5	39
103	Review of select causes of drug-induced AKI. Expert Review of Clinical Pharmacology, 2015, 8, 367-371.	3.1	27
104	The Authors Reply. Kidney International, 2015, 88, 200.	5.2	0
105	<sc>HIV</sc> and <sc>HCV</sc> Medications in End-stage Renal Disease. Seminars in Dialysis, 2015, 28, 397-403.	1.3	4
106	Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal of Kidney Diseases, 2015, 66, 857-868.	1.9	100
107	The Urine Sediment as a Biomarker of Kidney Disease. American Journal of Kidney Diseases, 2015, 66, 748-755.	1.9	102
108	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1291-1299.	4.5	80

#	ARTICLE	IF	CITATIONS
109	American Society of Nephrology Quiz and Questionnaire 2014. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 903-909.	4.5	1
110	Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. Iranian Journal of Kidney Diseases, 2015, 9, 3-13.	0.1	66
111	ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?. BioMed Research International, 2014, 2014, 1-7.	1.9	15
112	Magnetic Resonance Imaging in ESRD Patients: What are the Options?. Seminars in Dialysis, 2014, 27, 610-613.	1.3	0
113	Nephrotoxic effects of designer drugs: synthetic is not better!. Nature Reviews Nephrology, 2014, 10, 314-324.	9.6	48
114	Tubulointerstitial Injury Associated With Chemotherapeutic Agents. Advances in Chronic Kidney Disease, 2014, 21, 56-63.	1.4	25
115	Bile Acid Nephropathy in a Bodybuilder Abusing an Anabolic Androgenic Steroid. American Journal of Kidney Diseases, 2014, 64, 473-476.	1.9	52
116	Cancer and the Kidney: The Growth of Onco-nephrology. Advances in Chronic Kidney Disease, 2014, 21, 4-6.	1.4	21
117	American Society of Nephrology Quiz and Questionnaire 2013. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1132-1137.	4.5	4
118	American Society of Nephrology Quiz and Questionnaire 2013. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1319-1327.	4.5	1
119	Three feasible strategies to minimize kidney injury in 'incipient AKI'. Nature Reviews Nephrology, 2013, 9, 484-490.	9.6	58
120	AKI in a Hospitalized Patient with Cellulitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 658-664.	4.5	5
121	Urinary Eosinophils in AIN: Farewell to an Old Biomarker?. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1841-1843.	4.5	21
122	Macrophages at work: phagocytosis of urinary fungi. CKJ: Clinical Kidney Journal, 2013, 6, 233-234.	2.9	2
123	Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney International, 2013, 83, 553-556.	5.2	61
124	Traditional Urinary Biomarkers in the Assessment of Hospital-Acquired AKI. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 167-174.	4.5	57
125	Onco-Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1713-1721.	4.5	249
126	Renal Replacement Therapies for Prevention of Radiocontrast-induced Nephropathy: A Systematic Review. American Journal of Medicine, 2012, 125, 66-78.e3.	1.5	113

#	ARTICLE	IF	CITATIONS
127	Drug use and nephrotoxicity in the intensive care unit. <i>Kidney International</i> , 2012, 81, 1172-1178.	5.2	96
128	Imaging Patients With Kidney Disease: How Do We Approach Contrast-Related Toxicity?. <i>American Journal of the Medical Sciences</i> , 2011, 341, 215-221.	1.1	25
129	Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2740-2749.	4.5	98
130	Recurrent flank pain from 'lobster claw'. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 274-275.	2.9	0
131	Acute tubular necrosis and pre-renal acute kidney injury: utility of urine microscopy in their evaluation- a systematic review. <i>International Urology and Nephrology</i> , 2010, 42, 425-433.	1.4	90
132	Toxic Nephropathies: Core Curriculum 2010. <i>American Journal of Kidney Diseases</i> , 2010, 55, 399-409.	1.9	13
133	Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. <i>Kidney International</i> , 2010, 78, 1060-1063.	5.2	83
134	Urine Microscopy Is Associated with Severity and Worsening of Acute Kidney Injury in Hospitalized Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 402-408.	4.5	106
135	Nephrotoxicity From Chemotherapeutic Agents: Clinical Manifestations, Pathobiology, and Prevention/Therapy. <i>Seminars in Nephrology</i> , 2010, 30, 570-581.	1.6	235
136	Renal Vulnerability to Drug Toxicity. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1275-1283.	4.5	296
137	Current Status of Gadolinium Toxicity in Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 461-469.	4.5	219
138	Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. <i>American Journal of Medicine</i> , 2009, 122, 322-328.	1.5	153
139	Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 519-525.	2.0	41
140	NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Recommendations for Gadolinium-Based Contrast Use in Patients with Kidney Disease. <i>Seminars in Dialysis</i> , 2008, 21, 171-173.	1.3	14
141	NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Tissue Deposition of Gadolinium and Development of NSF: A Convergence of Factors. <i>Seminars in Dialysis</i> , 2008, 21, 150-154.	1.3	30
142	Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast: What's a Nephrologist to Do?. <i>Seminars in Dialysis</i> , 2008, 21, 121-122.	1.3	1
143	Diagnostic Value of Urine Microscopy for Differential Diagnosis of Acute Kidney Injury in Hospitalized Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1615-1619.	4.5	149
144	Bisphosphonate nephrotoxicity. <i>Kidney International</i> , 2008, 74, 1385-1393.	5.2	325

#	ARTICLE	IF	CITATIONS
145	Gadolinium-Induced Nephrogenic Systemic Fibrosis in Patients with Kidney Disease. American Journal of Medicine, 2007, 120, 561-562.	1.5	41
146	Increased Mortality in Chronic Kidney Disease: A Call to Action. American Journal of the Medical Sciences, 2006, 331, 150-153.	1.1	44
147	Pharmacology. American Journal of Kidney Diseases, 2005, 46, 1129-1139.	1.9	8
148	Drug-induced nephropathy: an update. Expert Opinion on Drug Safety, 2005, 4, 689-706.	2.4	124
149	Renin-angiotensin-aldosterone system: Fundamental aspects and clinical implications in renal and cardiovascular disorders. Journal of Nuclear Cardiology, 2003, 10, 184-196.	2.1	50
150	Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. Expert Opinion on Drug Safety, 2003, 2, 37-47.	2.4	10
151	Drug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity. American Journal of the Medical Sciences, 2003, 325, 349-362.	1.1	194
152	COX-2 selective inhibitors: analysis of the renal effects. Expert Opinion on Drug Safety, 2002, 1, 53-64.	2.4	31
153	Medical Management of Kidney and Electrolyte Disorders. Annals of Internal Medicine, 2001, 135, 392.	3.9	0
154	Trimethoprim-Induced Hyperkalaemia. Drug Safety, 2000, 22, 227-236.	3.2	59
155	Review Articles: Approach to Patients with Intradialytic Hypotension: A Focus on Therapeutic Options. Seminars in Dialysis, 1999, 12, 175-181.	1.3	20
156	Fellows Forum in Dialysis edited by Mark A. Perazella: Chemical Ablation of Parathyroid Hyperplasia for Recurrent Secondary Hyperparathyroidism in an Autograft. Seminars in Dialysis, 1998, 11, 249-252.	1.3	0
157	Midodrine. Seminars in Dialysis, 1997, 10, 245-247.	1.3	9
158	Acute Nonspecific Illness in an AIDS Patient with Dysphagia. Hospital Practice (1995), 1994, 29, 39-47.	1.0	1